Treatment with CFM 4.16 reduced the activation and/expression of MET in parental, TKI resistant and gemcitabine resistant NSCLC cells (Figure 2A–2C, and Supplementary Figure 1A). Here, MET is linked to non-small cell lung carcinoma.